期刊
CURRENT MEDICINAL CHEMISTRY
卷 30, 期 3, 页码 255-270出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867329666220328125206
关键词
Nanotechnology; brain tumour; Alzheimer's disease; nanoparticles; blood-brain barrier; drug delivery
Nanotechnology involves manipulating shape and size at the nanoscale to design and create structures, devices, and systems. It has shown great potential in improving drug delivery and overcoming the blood-brain barrier for treating brain disorders such as brain cancer and Alzheimer's disease. The use of nanomaterials in diagnostics and controlled drug delivery systems holds promise for enhancing the efficacy of treatments. However, further research is needed to ensure the safety and effectiveness of nanotechnology-assisted drugs.
Nanotechnology is the process of modulating shape and size at the nanoscale to design and manufacture structures, devices, and systems. Nanotechnology's prospective breakthroughs are incredible, and some cannot even be comprehended right now. The blood-brain barrier, which is a prominent physiological barrier in the brain, limits the adequate elimination of malignant cells by changing the concentration of therapeutic agents at the target tissue. Nanotechnology has sparked interest in recent years as a way to solve these issues and improve drug delivery. Inorganic and organic nanomaterials have been found to be beneficial for bioimaging approaches and controlled drug delivery systems. Brain cancer (BC) and Alzheimer's disease (AD) are two of the prominent disorders of the brain. Even though the pathophysiology and pathways for both disorders are different, nanotechnology with common features can deliver drugs over the BBB, advancing the treatment of both disorders. This innovative technology could provide a foundation for combining diagnostics, treatments, and delivery of targeted drugs to the tumour site, further supervising the response and designing and delivering materials by employing atomic and molecular elements. There is currently limited treatment for Alzheimer's disease, and reversing further progression is difficult. Recently, various nanocarriers have been investigated to improve the bioavailability and efficacy of many AD treatment drugs. Nanotechnology-assisted drugs can penetrate the BBB and reach the target tissue. However, further research is required in this field to ensure the safety and efficacy of drug-loaded nanoparticles. The application of nanotechnology in the diagnosis and treatment of brain tumours and Alzheimer's disease is briefly discussed in this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据